louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03119727: Clinical Evaluation of FreeO2 (Version 4) in All Patients Receiving Oxygen
Official title: Clinical Evaluation of the Automatic Oxygen Adjustment by FreeO2 in a Medical Population in Hospital
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Respiratory Disease
Respiratory Failure
COPD Exacerbation
Asthma
Pneumonia
Lead sponsor: Laval University
Sponsor class: OTHER
First posted: 2017-04-19
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Evaluation of automatic titration of oxygen with a new version of FreeO2 (V4)

Detailed description: In the previous studies, the investigators used many times automatic titration of oxygen on spontanous breathing patient (FreeO2 device) with a prototype develop in our lab in collaboration with Laval university. In this study, we want to evaluate the new version of the FreeO2 device (V4)

Eligibility criteria: Inclusion Criteria:

* Age \> or = 18 years old
* Patient receiving oxygen between 1 to 6 lpm for medical pathology
* Admitted to a medical service for less than 72 hours (emergency room not included)

Exclusion Criteria:

* Unreliable SpO2 signal
* Emergency or intensive care hospitalization
* Absence of NIV or intubation criteria at baseline
* Sleep apnea not paired
* Long-term Oxygen Therapy
* Active delirium and cognitive impairment preventing informed consent

Primary outcomes:
measure: % of time in the set SpO2 target
timeFrame: During 3 days of hospitalization or until Oxygen weaning
Secondary outcomes:
measure: Oxygenation data
timeFrame: 3 hospitalisations day or until Oxygen weaning
Other outcomes:
Locations:
city: Quebec
country: Canada
facility: IUCPQ-UL
Study officials:
References:
Clinical trial NCT01644227: Dual Mobility Cup in Total Hip Arthroplasty Preventing Dislocation in Patients at Risk
Official title: Dual Mobility Cup in Total Hip Arthroplasty Preventing Dislocation in Patients at Risk
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Femoral Neck Fracture
Osteoarthritis
Keywords: Hip surgery
dual mobility cup
dislocation
total hip arthroplasty
Lead sponsor: Sundsvall Hospital
Sponsor class: OTHER
First posted: 2012-07-19
Enrollment: 34
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients operated with an cemented dual mobility cups at Sundsvall hospital between 2009-2012.

Indications for surgery are recurrent dislocation and patients at risk for dislocation mainly due to comorbidity, neuromuscular, psychiatric or cognitive disorders.

Brief summary: Retrospectively study reviewing 34 patients operated with dual mobility cups in total hip arthroplasty between January 2009 and June 2012 at Sundsvall Hospital.

Hypothesis: The dual mobility socket reduce the rate of dislocation in patient at high risk but increase the incidence of postoperative infection.

Detailed description: Retrospectively study reviewing 34 patients operated with dual mobility cups in total hip arthroplasty between January 2009 and June 2012 at Sundsvall Hospital.

Indications for surgery is recurrent dislocation or patients at risk for dislocation after total hip arthroplasty suffering osteoarthritis or femoral neck fracture.

Patients are followed recording complications, reoperations, functional outcome (Harris hip score and EQ5D) in june 2012.

Eligibility criteria: Inclusion Criteria:

* operated with an cemented dual mobility socket at Sundsvall hospital

Primary outcomes:
measure: Prosthetic dislocation
timeFrame: 2012 (up to 3 years postoperatively)
Secondary outcomes:
measure: Complication
timeFrame: 2012 (up to 3 years postoperatively)
measure: Hip function
timeFrame: 2012 (up to 3 years postoperatively)
measure: Quality of life
timeFrame: 2012 (up to 3 years postoperatively)
Other outcomes:
Locations:
city: Sundsvall
country: Sweden
facility: Orthopaedic department
state: Västernorrlands län
Study officials:
affiliation: Landstinget Västernorrland
name: Arkan S Sayed Noor, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mukka SS, Mahmood SS, Sjoden GO, Sayed-Noor AS. Dual mobility cups for preventing early hip arthroplasty dislocation in patients at risk: experience in a county hospital. Orthop Rev (Pavia). 2013 Jun 11;5(2):48-51. doi: 10.4081/or.2013.e10. Print 2013 Jun 7.
Clinical trial NCT00817427: Sleep Disturbances as a Risk Factor in Chronic Kidney Disease
Official title: Sleep Disturbance as a Non-Traditional Risk Factor in CKD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Kidney Disease
Keywords: Chronic Kidney Disease
Poor sleep
CKD
Kidney Failure
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2009-01-06
Enrollment: 40
Sex: ALL
Minimum age (years): 21
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL

Brief summary: This study is designed to determine if either short night time sleep or poor night time sleep could be a risk factor for increasing the rate at which kidney function deteriorates in persons with mild to moderate kidney disease.


Eligibility criteria: Inclusion Criteria:

* Mild to Moderate CKD
* Healthy controls age and gender matched to CKD subjects
* Regular bedtimes of at least 6h/night, sedentary lifestyle

Exclusion Criteria:

* Diabetes
* Current or previous dialysis for more than 1 month
* Uncontrolled hypertension
* Heart failure
* Liver disease
* HIV
* Hemoglobin \< 10.5 g/dl
* Treatment with EProcrit, Epogen, or Aranesp
* Bone or organ transplant,
* Use of immunosuppressive drugs within past 6 months
* Current oral contraceptive use
* Current pregnancy
* Chemotherapy for malignancy within past 2 years

Primary outcomes:
measure: Comparison of chronobiological profiles of renin/aldosterone, sympatho-vagal balance and CV function in CKD subjects to controls at baseline and after extended sleep in CKD subjects and after decreased time and quality of sleep in control subjects.
timeFrame: Immediately after intervention.
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: The University of Chicago
state: Illinois
Study officials:
affiliation: University of Chicago
name: Eve Van Cauter, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00231127: Osteoporosis and Chronic Obstructive Pulmonary Disease (COPD)
Official title: Osteoporosis and COPD (Making of a Database)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COPD
Osteoporosis
Osteopenia
Keywords: COPD
Osteoporosis
Osteopenia
Glucocorticoids
GOLD
BODE
Lead sponsor: Catharina Ziekenhuis Eindhoven
Sponsor class: OTHER
First posted: 2005-10-04
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Chronic Obstructive Pulmonary Disease Patients visiting the pulmonary outpatient clinic of the Catharina Hospital Eindhoven.

Brief summary: The goals of the trial are:

* To determine the prevalence of osteoporosis in subgroups of COPD patients.
* To look for risk factors of osteoporosis in COPD patients.
* To create sub-groups for prospective research concerning the effects of bisphosphonates on osteoporosis variables in COPD patients.

Detailed description: Background:

Osteoporosis is defined as a systemically skeletal disorder characterized by a low bone mass and deterioration of the micro-architecture of the bone and is therefore associated with a higher risk of fractures. Large epidemiological studies to determine the incidence and prevalence of osteoporosis in COPD patients in different stages of their disease are not available. The etiology of osteoporosis in COPD patients is complex and depends on multiple factors.

Goals of the Trial:

* To determine the prevalence of osteoporosis in subgroups of COPD patients.
* To look for risk factors of osteoporosis in COPD patients.
* To create sub-groups for prospective research concerning the effects of bisphosphonates on osteoporosis variables in COPD patients.

Study Design:

Patients diagnosed with COPD (according to the American Thoracic Society \[ATS\] guidelines and divided in stages according to the Global Initiative on Obstructive Lung Diseases \[GOLD\]-classification) who visit the out-patient clinic of pulmonology of the Catharina Hospital Eindhoven will be asked to participate in the trial. A database will be created (prospectively) of the (medical) information about these patients, which will be analysed retrospective. To gather information we will use the medical records, a questionnaire, a blood sample, long function testing including a 6-minute walking test and a DEXA-scan.

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Men and women
* COPD according to the ATS-guidelines, divided in severity according to the GOLD criteria
* Written consent

Exclusion Criteria:

* Age \< 18 years
* No written consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Eindhoven
country: Netherlands
facility: Catharina Hospital Eindhoven
state: Noord-Brabant
Study officials:
affiliation: Catharina Hospital Eindhoven (Department of Pulmonology)
name: Lidwien Graat, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00734227: TIPS Versus Portacaval Shunt for Acute Bleeding Varices in Cirrhosis
Official title: TIPS Versus Portacaval Shunt for Acute Bleeding Varices in Cirrhosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bleeding
Keywords: Survival and control of hemorrhage
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
First posted: 2008-08-14
Enrollment: 153
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In unselected cirrhotic patients with acute portal hypertension-related bleeding to compare the effectiveness in control of bleeding, mortality rate, duration of life, quality of life, and economic costs of two widely used treatment measures: (1) emergency transjugular intrahepatic portal-systemic shunt (TIPS), and (2) emergency portacaval shunt.


Eligibility criteria: Inclusion Criteria:

* All patients with UGI bleeding who are shown to have the findings of cirrhosis and esophagogastric varices or portal hypertensive gastropathy and require 2 or more units of blood transfusion will be included.

Exclusion Criteria:

* None

Primary outcomes:
measure: Survival
timeFrame: 10 years
Secondary outcomes:
measure: Control of bleeding and quality of life
timeFrame: 10 years
Other outcomes:
Locations:
city: San Diego
country: United States
facility: UCSD Medical Center
state: California
Study officials:
affiliation: UCSD Medical Center
name: Marshall J. Orloff, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Orloff MJ. Fifty-three years' experience with randomized clinical trials of emergency portacaval shunt for bleeding esophageal varices in Cirrhosis: 1958-2011. JAMA Surg. 2014 Feb;149(2):155-69. doi: 10.1001/jamasurg.2013.4045.
citation: Orloff MJ, Vaida F, Haynes KS, Hye RJ, Isenberg JI, Jinich-Brook H. Randomized controlled trial of emergency transjugular intrahepatic portosystemic shunt versus emergency portacaval shunt treatment of acute bleeding esophageal varices in cirrhosis. J Gastrointest Surg. 2012 Nov;16(11):2094-111. doi: 10.1007/s11605-012-2003-6. Epub 2012 Sep 25.
Clinical trial NCT04574427: INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue
Official title: INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Head and Neck Cancer
Penile Cancer
Keywords: surgery
fluorescent c-met tracer
penile
tongue
Lead sponsor: The Netherlands Cancer Institute
Sponsor class: OTHER
First posted: 2020-10-05
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with tongue cancer scheduled for primary tumour resection OR Patients with penile cancer scheduled for primary tumour resection.

Brief summary: In this study we evaluate the feasibility of intraoperative visualization of penile and tongue tumours using the fluorescent tracer EMI-137.

Detailed description: This is a single-center, non-randomized, prospective interventional pilot study. Feasibility of intraoperatively visualizing tumour (margins) in penile and tongue tumours using EMI-137 will be investigated. Patients, ≥ 18 years of age, with ≥T1 penile or tongue cancer undergoing primary tumour surgery will be included. All patients will receive an intravenous bolus injection of EMI-137 prior to surgery. Main study parameters/endpoints are: Intraoperative visualization of primary penile or tongue tumours using a dedicated clinical fluorescence camera. The in vivo detected fluorescence signal will be correlated to ex vivo measurements and pathological assessment of the ex-cised tissue.

Eligibility criteria: Inclusion Criteria:

* Written informed consent, prior to performing any protocol related procedures.
* Age ≥ 18 years at time of study entry.
* ≥ T1 penile or tongue squamous cell cancer
* Scheduled for surgical primary tumour resection

Exclusion Criteria:

* Involvement in the planning and/or conduct of the study.
* Pregnant woman
* Abstaining from usage of two forms of barrier contraceptive or actively planning pregnancy within 90 days.
* Severe kidney insufficiency

Primary outcomes:
measure: tumour visualization by means of c-MET targeted fluores-cence imaging
timeFrame: peri-operative
Secondary outcomes:
measure: Lymph node visualization by means of c-MET targeted fluores-cence imaging
timeFrame: peri-operative
measure: Dysplasia or Cis by means of c-MET targeted fluores-cence imaging
timeFrame: Peri-operative
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: The Netherlands Cancer Institute / Antoni van Leeuwenhoek
state: Noord-Holland
Study officials:
affiliation: The Netherlands Cancer Institute
name: Baris Karakullukcu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05895227: Hemorrhagic Complications of Transvaginal Oocyte's Retrieval: an Update.
Official title: Hemorrhagic Complications of Transvaginal Oocyte's Retrieval: an Update.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: ART
Infertility
Lead sponsor: Istituto Clinico Humanitas
Sponsor class: OTHER
First posted: 2023-06-08
Enrollment: 13193
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients that underwent oocyte retrieval procedure at Humanitas Fertility Center during the period January 2017 - December 2022, in IVF/ICSI cycles and fertility preservation both in oncological patients and in patients requesting oocyte storage for deferring motherhood.

Brief summary: The goal of this retrospective analysis is to focus on peritoneal bleeding after oocyte retrieval and to further investigate factors related to this specific complication and if hemorrhagic complication rate modifications can be observed.

Detailed description: The main aim is to update our knowledge on oocyte retrieval complication, focusing specifically on hemorrhagic / hemoperitoneum rate.

All retrievals will be retrieved in IVF/ICSI cycles and Fertility Preservation both in oncological patients and in patients requesting oocyte storage for deferring motherhood.

Data collection goes from January 2017 to December 2022.

Eligibility criteria: Inclusion Criteria:

* patients that underwent a procedure of oocyte transvaginal retrieval for IVF/ intracytoplasmatic sperm injection (ICSI) cycles and fertility preservation

Exclusion Criteria:

-

Primary outcomes:
measure: Hemoperitoneum after oocyte transvaginal retrieval
timeFrame: Oocyte retrievals in the period January 2017- December 2022
Secondary outcomes:
measure: Operator of the procedure
timeFrame: 6 years
measure: Hemoglobin level before and after procedure
timeFrame: 6 years
measure: Time of symptoms onset
timeFrame: 6 years
measure: Loss of blood during procedure
timeFrame: 6 years
measure: Incidence compared to past case history
timeFrame: 6 years
measure: Need for hospitalization
timeFrame: 6 years
Other outcomes:
Locations:
Study officials:
affiliation: Istituto Clinico Humanitas
name: Paolo Emanuele Levi Setti, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03578627: Stress and Immunity Breast Cancer Project
Official title: Psychological/Immunity Studies With Women With Cancer Previously
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer Stage II
Breast Cancer Stage III
Lead sponsor: Ohio State University Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2018-07-06
Enrollment: 231
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: An investigative study of the effectiveness of the BioBehavioral Intervention on Stage II/III breast cancer patients. A total of 231 patients were split between an assessment-only control group and an experimental group receiving the Intervention and assessment. The goal of the Intervention is to use psychological, behavioral, and biologic methods with the primary goal of reducing cancer recurrence.


Eligibility criteria: Inclusion Criteria:

* Stage II or III breast cancer diagnosis prior to adjuvant therapy

Exclusion Criteria:

-

Primary outcomes:
measure: Recurrence event
timeFrame: Ten years
measure: Recurrence time
timeFrame: Ten years
Secondary outcomes:
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Ohio State University Medical Center
state: Ohio
Study officials:
affiliation: The Ohio State University Comprehensive Cancer Center
name: Barbara Andersen
role: PRINCIPAL_INVESTIGATOR
References:
citation: Conley CC, Andersen BL. Lemons to lemonade: Effects of a biobehavioral intervention for cancer patients on later life changes. Health Psychol. 2019 Mar;38(3):206-216. doi: 10.1037/hea0000717.
Clinical trial NCT01115127: Myo-inositol and Melatonin in Pre-menopausal Women
Official title: Myo-inositol and Melatonin in Menopausal Transition. A Prospective, Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Pre-menopausal Irregular Cycles and Bleedings
Keywords: pre-menopause
melatonin
myo-inositol
Lead sponsor: University of Messina
Sponsor class: OTHER
First posted: 2010-05-04
Enrollment: 90
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether myo-inositol and melatonin, or myo-inositol alone, or melatonin alone, are effective in normalizing irregular bleeding and anovulatory cycles in pre-menopausal women.

Detailed description: Melatonin has produced a remarkable significant improvement of thyroid function, positive changes of gonadotropins towards reduced levels, and in some women a re-acquisition of normal menstrual cycle. Furthermore, an abrogation of menopause-related depression, amelioration of hot-flashes and improvement of quality and duration of sleep has been reported.

Myo-inositol is involved in several aspects of human reproduction. Elevated concentrations of myo-inositol in human follicular fluids appear to play a positive function in follicular maturity and provide a marker of good quality oocytes. Nevertheless its positive role in PCOS women is a consequence of a defect in the insulin signalling pathway (inositol-containing phosphoglycan mediators) that seems to be primarily implicated in the pathogenesis of insulin resistance

Eligibility criteria: Inclusion Criteria:

* all pre-menopausal women with irregular cycles and bleedings

Exclusion Criteria:

* pre-menopausal women who take hormonal drugs

Primary outcomes:
measure: Normalizing irregular bleeding and anovulatory cycles in pre-menopausal women.
timeFrame: 12 months
Secondary outcomes:
measure: Serum assays of thyroid hormones.
timeFrame: 12 months
measure: Assays of gonadotropins and estradiol serum levels
timeFrame: 12 months
measure: Evaluation of metabolic markers (insulin, glucose, total cholesterol, HDL-cholesterol, triglycerides).
timeFrame: 12 months
measure: Variation of blood pressure.
timeFrame: 12 months
measure: Variation of mood, hot flashes, quality of sleep.
timeFrame: 12 months
Other outcomes:
Locations:
city: Messina
country: Italy
facility: University Hospital
Study officials:
affiliation: University of Messina
name: Rosario D'Anna, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06008327: Comparison Of Outcome Of Treatment OF Topical 15%TCA VS Topical 0.05% Tretinoin In Treatment Of Acanthosis Nigricans
Official title: Comparison Of The Outcome Of Treatment Of Topical 15% Trichloroacetic Acid Versus Topical 0.05% Tretinoin In The Treatment Of Acanthosis Nigricans
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acanthosis Nigricans
Lead sponsor: Jinnah Postgraduate Medical Centre
Sponsor class: OTHER_GOV
First posted: 2023-08-23
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Acanthosis nigricans (AN) is a dermatosis with aesthetic implications and is characterized by the focal or diffuse development of a velvety, hyperpigmented cutaneous thickening in intertriginous areas. Trichloroacetic acid (TCA), a superficial chemical exfoliative agent has shown efficacy in treating acanthosis nigricans. Data from this would help in establishing it as a treatment of choice thereby lead to reduction in cost and benefit the patient both financially and psychologically.

Detailed description: Acanthosis nigricans is common, although exact prevalence depends upon the racial makeup of the population studied. Exact pathogenesis is unknown, elevated insulin concentrations result in direct and indirect activation of IGF-1 receptors on keratinocytes and fibroblasts, leading to proliferation. This hyperpigmentation, which has poorly defined borders, usually occurs in skin fold areas symmetrically, such as the back of the neck, axilla and groin, and may rarely involve oral mucosa. The lesions may be related to a wide range of benign conditions and may occur as a paraneoplastic manifestation of various potentially fatal malignancies.

Eligibility criteria: Inclusion Criteria:

* Patients who will present with acanthosis nigricans as per operational definition will be included in the study.

  * Either gender.
  * Age 20-50 years.

Exclusion Criteria:

Pregnancy.

* Breastfeeding.
* Patients with history of skin resurfacing by dermabrasion, chemical peels and facial laser within the preceding 9 months.
* Patients with history of hypersensitivity.
* Malignant Acanthosis Nigricans.
* Drug Induced Acanthosis Nigricans.

Primary outcomes:
measure: EFFICACY OF TOPICAL 15%TRICHLOROACETIC ACID VERSUS 0.05% TOPICAL TRETINOIN IN ACANTHOSIS NIGRICANS
timeFrame: It will be assessed upto 02 months
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: JPMC
state: Sindh
Study officials:
affiliation: Jpmc
name: Parisa Sanawar, FCPS
role: PRINCIPAL_INVESTIGATOR
affiliation: Jpmc
name: Nazia Jabeen, FCPS
role: PRINCIPAL_INVESTIGATOR
affiliation: Jpmc
name: Fazia Inam, FCPS
role: PRINCIPAL_INVESTIGATOR
References: